- Novel anti-fungal agents effective against drug-resistant Candida strains.
- Reduced toxicity compared to traditional treatments like amphotericin B.
- Suitable for high-risk groups, including HIV and cancer patients.
OVERVIEW
Georgetown University researchers developed a novel class of anti-fungal drugs exhibiting high potency against Candida albicans, a prevalent cause of fungal infections in humans. These compounds, derived from 1,2-benzisothiazolinone and isoindolinone, offer a promising solution to combat drug-resistant strains and reduce toxicity associated with current treatments. A prime application includes treating oral and genital candidiasis, especially in immunocompromised patients like those with HIV or cancer. These drugs can potentially address severe fungal infections with improved efficacy and safety profiles.
BACKGROUND
Fungal infections, particularly candidiasis, pose significant health risks, especially to immunocompromised individuals. Current treatments are plagued by resistance and toxicity issues. This innovation introduces new compounds that effectively target Candida albicans, offering a needed alternative in an era of increasing antifungal resistance and limited therapeutic options.
Benefit
Effective against drug-resistant strains: These new compounds provide an alternative for infections unresponsive to current treatments such as fluconazole.Lower toxicity: Compared to amphotericin B, these agents offer a safer profile, especially for intravenous administration.Broad application: Effective for both oral and genital candidiasis, enhancing treatment options for diverse infections.Enhanced safety for immunocompromised patients: These compounds are particularly beneficial for individuals with weakened immune systems, reducing the risk of severe infections.
Market Application
Treatment of oral candidiasis (oral thrush): Providing a new solution for a common and often recurring infection.Treatment of genital candidiasis (vaginitis): Offering an effective alternative for a widespread condition affecting millions.Management of candidiasis in immunocompromised patients: Critical for those undergoing cancer treatment or living with HIV.Addressing antifungal resistance: Filling a crucial gap in the market by targeting resistant strains of Candida albicans.
Publications
US Issued Patent No. 9,040,715
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
